Press Release · Press Releases · Asia-Pacific
Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC)....
This press release summary is reproduced from the issuer's public feed.
Read the full release at PR NewswireOriginal publisher: PR Newswire
Spotted an error? Request a correction · Corrections Policy
Related stories
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) across PD-L1 expression levels First-line treatment options...
PR Newswire ·
Ping An Highlights Green Development Initiatives at International Communication Seminar in Shenzhen Ahead of APEC 2026
HONG KONG and SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- The Seminar on International Communication of Chinese and Foreign Enterprises' Green Development and Global Contributions was held at the Ping An Finance Center in Shenzhen on October 23. Hosted by the China Public Relations...
PR Newswire ·
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...
PR Newswire ·
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune,...
PR Newswire ·
ST Engineering iDirect and MBSat Partner to Build Next-Generation Sovereign Connectivity Services Across Oman and the Middle East
Intuition ground system selected to support MBSat's planned 2027 service launch, enabling accelerated deployment, dynamic resource management and scalable service growth HERNDON, Va., Oct. 25, 2026 /PRNewswire/ -- ST Engineering iDirect today announced a strategic partnership with...
PR Newswire ·
Katarská iniciativa Roky kultury oznámila partnerské země až do roku 2030
V následujících letech se partnery Roků kultury stanou Itálie, Nizozemsko, Švýcarsko, Portugalsko a Španělsko. DAUHÁ, Katar, 25. října 2026 /PRNewswire/ -- Iniciativa Roky kultury dnes oznámila jména katarských kulturních partnerů až do roku 2030. V návaznosti na již dříve oznámená...
PR Newswire ·